Published 2 days ago

Strategic Partnership Between Matica Bio and Mongoose Bio to Accelerate TCR-T Cell Therapy Development

Summary by ADKhabar

COLLEGE STATION, Texas--(BUSINESS WIRE)--Matica Biotechnology, a leading Texas-based viral vector Contract Development and Manufacturing Organization (CDMO), has announced a strategic partnership with the innovative biotech company, Mongoose Bio. This partnership is focused on the full development and production of lentivirus for Mongoose Bio's T cell receptor-engineered T cell (TCR-T) pipeline for cancer treatment. Under the

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated2 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Strategic Partnership Between Matica Bio and Mongoose Bio to Accelerate TCR-T Cell Therapy Development

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics